Dartmouth-Hitchcock Medical Center / Dartmouth-Hitchcock Manchester
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gifford, Alex H
NCT06449677: Bionic Pancreas in CFRD

Recruiting
3
150
US
iLet Bionic Pancreas System (BP), Usual Care (UC)
Jaeb Center for Health Research, Cystic Fibrosis Foundation, Massachusetts General Hospital, Beta Bionics, Inc.
Cystic Fibrosis-related Diabetes
11/25
03/26
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
NCT06159725: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis

Recruiting
1/2
41
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Persistent Infection, Cystic Fibrosis
08/25
08/25
AEROW, NCT05248230: 4D-710 in Adult Patients With Cystic Fibrosis

Recruiting
1/2
40
US
4D-710
4D Molecular Therapeutics
Cystic Fibrosis Lung
12/26
01/30
NCT06016088: A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Recruiting
1/2
72
US, RoW
RSP-1502, Tobramycin inhalation solution
Respirion Pharmaceuticals Pty Ltd
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
12/25
12/25
SIMPLIFY-HS, NCT06350461: Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study

Completed
N/A
370
US
Discontinuation of hypertonic saline (HS), Continuation of hypertonic saline (HS)
Nicole Hamblett, Cystic Fibrosis Foundation, Dartmouth-Hitchcock Medical Center, University of Washington
Cystic Fibrosis
07/22
07/22
SIMPLIFY-DN, NCT06350474: Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

Completed
N/A
477
US
Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
Nicole Hamblett, Cystic Fibrosis Foundation, Dartmouth-Hitchcock Medical Center, University of Washington
Cystic Fibrosis
07/22
07/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gifford, Alex H
NCT06449677: Bionic Pancreas in CFRD

Recruiting
3
150
US
iLet Bionic Pancreas System (BP), Usual Care (UC)
Jaeb Center for Health Research, Cystic Fibrosis Foundation, Massachusetts General Hospital, Beta Bionics, Inc.
Cystic Fibrosis-related Diabetes
11/25
03/26
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
NCT06159725: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis

Recruiting
1/2
41
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Persistent Infection, Cystic Fibrosis
08/25
08/25
AEROW, NCT05248230: 4D-710 in Adult Patients With Cystic Fibrosis

Recruiting
1/2
40
US
4D-710
4D Molecular Therapeutics
Cystic Fibrosis Lung
12/26
01/30
NCT06016088: A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Recruiting
1/2
72
US, RoW
RSP-1502, Tobramycin inhalation solution
Respirion Pharmaceuticals Pty Ltd
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
12/25
12/25
SIMPLIFY-HS, NCT06350461: Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study

Completed
N/A
370
US
Discontinuation of hypertonic saline (HS), Continuation of hypertonic saline (HS)
Nicole Hamblett, Cystic Fibrosis Foundation, Dartmouth-Hitchcock Medical Center, University of Washington
Cystic Fibrosis
07/22
07/22
SIMPLIFY-DN, NCT06350474: Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

Completed
N/A
477
US
Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
Nicole Hamblett, Cystic Fibrosis Foundation, Dartmouth-Hitchcock Medical Center, University of Washington
Cystic Fibrosis
07/22
07/22

Download Options